Hikma Pharmaceuticals Statistics

Total Valuation

Hikma Pharmaceuticals has a market cap or net worth of GBP 4.33 billion. The enterprise value is 5.15 billion.

Market Cap	4.33B
Enterprise Value	5.15B

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date	Feb 21, 2025
Ex-Dividend Date	Aug 15, 2024

Share Statistics

Hikma Pharmaceuticals has 221.75 million shares outstanding. The number of shares has increased by 0.59% in one year.

Current Share Class	n/a
Shares Outstanding	221.75M
Shares Change (YoY)	+0.59%
Shares Change (QoQ)	+0.46%
Owned by Insiders (%)	2.24%
Owned by Institutions (%)	54.50%
Float	155.34M

Valuation Ratios

The trailing PE ratio is 19.40 and the forward PE ratio is 10.90. Hikma Pharmaceuticals's PEG ratio is 1.66.

PE Ratio	19.40
Forward PE	10.90
PS Ratio	1.80
PB Ratio	2.39
P/TBV Ratio	4.59
P/FCF Ratio	12.73
P/OCF Ratio	n/a
PEG Ratio	1.66

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.54, with an EV/FCF ratio of 15.12.

EV / Earnings	22.82
EV / Sales	2.16
EV / EBITDA	7.54
EV / EBIT	9.12
EV / FCF	15.12

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.55.

Current Ratio	1.66
Quick Ratio	0.89
Debt / Equity	0.55
Debt / EBITDA	1.48
Debt / FCF	2.97
Interest Coverage	9.75

Financial Efficiency

Return on equity (ROE) is 12.88% and return on invested capital (ROIC) is 12.55%.

Return on Equity (ROE)	12.88%
Return on Assets (ROA)	9.40%
Return on Capital (ROIC)	12.55%
Revenue Per Employee	262,336
Profits Per Employee	24,782
Employee Count	9,100
Asset Turnover	0.64
Inventory Turnover	1.75

Taxes

In the past 12 months, Hikma Pharmaceuticals has paid 68.92 million in taxes.

Income Tax	68.92M
Effective Tax Rate	31.90%

Stock Price Statistics

The stock price has increased by +10.65% in the last 52 weeks. The beta is 0.41, so Hikma Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+10.65%
50-Day Moving Average	1,913.54
200-Day Moving Average	1,914.95
Relative Strength Index (RSI)	56.37
Average Volume (20 Days)	454,102

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hikma Pharmaceuticals had revenue of GBP 2.39 billion and earned 225.51 million in profits. Earnings per share was 1.01.

Revenue	2.39B
Gross Profit	1.15B
Operating Income	563.38M
Pretax Income	290.40M
Net Income	225.51M
EBITDA	667.83M
EBIT	563.38M
Earnings Per Share (EPS)	1.01

Full Income Statement

Balance Sheet

The company has 205.73 million in cash and 1.01 billion in debt, giving a net cash position of -803.93 million or -3.63 per share.

Cash & Cash Equivalents	205.73M
Total Debt	1.01B
Net Cash	-803.93M
Net Cash Per Share	-3.63
Equity (Book Value)	1.82B
Book Value Per Share	8.16
Working Capital	716.10M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 462.10 million and capital expenditures -121.86 million, giving a free cash flow of 340.25 million.

Operating Cash Flow	462.10M
Capital Expenditures	-121.86M
Free Cash Flow	340.25M
FCF Per Share	1.53

Full Cash Flow Statement

Margins

Gross margin is 47.99%, with operating and profit margins of 23.60% and 9.45%.

Gross Margin	47.99%
Operating Margin	23.60%
Pretax Margin	12.16%
Profit Margin	9.45%
EBITDA Margin	27.97%
EBIT Margin	23.60%
FCF Margin	14.25%

Dividends & Yields

This stock pays an annual dividend of 0.63, which amounts to a dividend yield of 3.22%.

Dividend Per Share	0.63
Dividend Yield	3.22%
Dividend Growth (YoY)	23.98%
Years of Dividend Growth	2
Payout Ratio	55.79%
Buyback Yield	-0.59%
Shareholder Yield	2.63%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Hikma Pharmaceuticals has an Altman Z-Score of 3.26 and a Piotroski F-Score of 7.

Altman Z-Score	3.26
Piotroski F-Score	7